Weber on Oncology

• ASCO 2018 New Biomarkers for Immunotherapy: The Microbiome and Beyond   Jeffrey Weber and April Salama discuss the pitfalls of current biomarkers to pick cancer treatments, the influence of the microbiome, and the search for peripheral blood markers.
  Medscape Oncology, June 28, 2018
• Key Melanoma Trials at ASCO Yield Encouraging Survival Data   The survival advantage seen in the COLUMBUS trial with a BRAF/MEK drug combination may be unprecedented, says Dr Jeffrey Weber.
  Medscape Oncology, June 22, 2018
• Immunotherapy Cost Problem May Require 'Revolutionary' Remedies   Can the meteoric costs associated with immunotherapy be reined in? Drs Weber and Hamid discuss solutions for this 'really difficult problem.'
  Medscape Oncology, June 21, 2018
• Cost Problem Only Getting Worse With IO Combos, Adjuvant Use   Drs Weber and Hamid discuss the increasing cost of immune-oncology therapy, particularly concerning as the number of patients using these agents in the adjuvant setting is likely to rise greatly.
  Medscape Oncology, June 21, 2018
• Lower-Dose Combo Immunotherapy Promising for Advanced Melanoma   Dr Jeffrey S. Weber reviews data from an open-label phase 1/2 trial assessing the efficacy and safety of combination pembrolizumab and reduced-dose ipilimumab in patients with advanced melanoma.
  Medscape Oncology, February 22, 2018
• Epacadostat + Pembro for Melanoma: Beneficial, Well Tolerated   This combination produced impressive response and disease control rates with good tolerability in treatment-naive patients with advanced melanoma.
  Medscape Oncology, November 30, 2017
• Adjuvant BRAF and MEK Inhibition for Melanoma: 'Impressive'   New at ESMO 2017, adjuvant dabrafenib/trametinib in stage III melanoma shows 'impressive' results in relapse-free survival.
  Medscape Oncology, October 31, 2017
• Ipi Plus Nivo for Melanoma Patients With Brain Metastases   Two recent ASCO abstracts show important results, possibly practice-changing, on immunologic treatment in melanoma patients with brain metastases.
  Medscape Oncology, October 20, 2017
• Adjuvant Nivolumab: New Standard of Care for Melanoma?   In resected melanoma, nivolumab improves recurrence-free survival with less toxicity. Dr Jeffrey Weber discusses results of the CheckMate 238 study presented at ESMO 2017
  Medscape Oncology, September 29, 2017
• Top Melanoma Studies to Be Presented at ASCO   Dr Jeffrey Weber previews five melanoma treatment studies that he considers the ones to watch; one, he predicts, will be practice-changing.
  Medscape Oncology, May 26, 2017
• Biomarkers to Determine Who Gets Checkpoint Inhibitors   Reviewing recent research, Dr Jeffrey Weber concludes that an amalgam of host- and tumor-related markers will be the best indication of which patients should receive checkpoint inhibitors.
  Medscape Oncology, April 03, 2017
• Rare Melanomas Prove 'Hard to Get' Using Immunotherapy   Dr Jeffrey Weber assesses the benefit of immunotherapies in two rare subtypes of melanoma and finds that rates of survival and duration of response trail well behind those associated with cutaneous melanoma.
  Medscape Oncology, March 13, 2017
• The Puzzling Prognostic Effect of LDH in Melanoma   Although LDH is a negative prognostic factor in melanoma, patients who receive checkpoint inhibitors may still have responses of long duration even when their LDH level is high.
  Medscape Oncology, March 06, 2017
• Two Ipilimumab Trials Show Survival Benefit, and More Toxicity   Dr Weber discusses two studies that show a clear survival advantage with ipilimumab, but at a significant price in toxicity.
  Medscape Oncology, October 31, 2016
• Stopping Immunotherapy Doesn't Stop Benefit   Two recent studies, as discussed by Dr Jeffrey Weber, indicate that melanoma patients who stop immunotherapy because of toxicity can do very well clinically over the long term.
  Medscape Oncology, October 10, 2016
• Is Immunotherapy Safe for Older Melanoma Patients?   How do adverse events from immunotherapy compare in younger vs older patients? Dr Weber comments on the safety of checkpoint inhibitors for our older patients.
  Medscape Oncology, September 22, 2016
• Will PD-1 Agents Edge Out Interferon in Adjuvant Melanoma?   Dr Jeffrey Weber reviews the current options for adjuvant therapy in patients with resected melanoma and looks ahead to the use of PD-1 antibodies in this setting.
  Medscape Oncology, August 12, 2016
• The 'C' Word Whispered in Metastatic Melanoma   Is cure a possibility for some patients with metastatic melanoma? Dr Jeffrey Weber discusses long-term survival from the KEYNOTE-001 and COMBI-d studies, which show 'very impressive data indeed.'
  Medscape Oncology, July 08, 2016
• Which Cancer Patient Is a Candidate for Immunotherapy?   Because immunotherapies are approved for multiple cancers, Drs Weber and Postow discuss choosing the right patient for immunotherapy, taking into account comorbidities and potential adverse events.
  Medscape Oncology, June 29, 2016
• Findings From NEMO, and Other Melanoma Highlights   In a preview of ASCO melanoma studies, the NEMO results suggest that binimetinib is reasonable for NRAS-mutated melanoma, and combo regimens continue to show strong outcomes, reports Dr Jeffrey Weber.
  Medscape Oncology, May 31, 2016